Biofrontera stabilizes shareholder structure

Biofrontera AG / Biofrontera stabilizes shareholder structure . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Block trade completed off-market
• Biofrontera enters essential growth phase with long-term investors

Leverkusen, 08 April 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on skin cancer, has stabilized its shareholder structure through an off market block trade of shares. Following intensive selling over the stock markets, the one million remaining shares owned by Dr. Carsten Maschmeyer, through his investment funds, were acquired by existing institutional investors in Biofrontera.

"Biofrontera is in an important growth phase. Developments in 2015 will be core to our future success, in particular with the preparations for the market entry of Ameluz in the USA. In addition, we will progress the indication expansion for basal cell carcinoma in Europe as quickly as possible. In this phase we are delighted by the confidence of investors taking up a block of shares on short notice, signalling their support for the Company's strategy." said Biofrontera's CEO, Prof. Hermann Lübbert.

The shareholder structure of Biofrontera AG is published and regularly updated on Biofrontera's homepage within the relevant reports.

Ends

Enquiries, please contact:

Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer, Chief Financial Officer	[phone] [e-mail] www.biofrontera.com
IR Germany: Brainwell Asset Solutions Jürgen Benker	[phone]
Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs	[phone]
IR UK: Seton Services Toni Vallen	[phone]
Financial PR: Gable Communications